Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug crawled time : 15:00 save search
InnoGI Technologies and Simulations Plus Combine Forces to Offer Next-Level Modeling Solutions for the Prediction of Oral Drug Performance
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
SLP | $45.01 -0.33% -0.33% 90K
|
Technology Services
|
| O: 0.86%
H: 0.68%
C: -2.3%
drug solutions for plus
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
VTVT | $24.04 -0.21% 3K
|
Health Technology
|
| O: 2.83%
H: 2.85%
C: 1.01%
drug pharmaceuticals glioblastoma
BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF ITS CONTROLLED SUBSTANCES DRUG PRODUCTION FACILITY IN GRANTS, NEW MEXICO AND OBTAINS $60 MILLION IN FINANCING
Published: 2024-03-12 (Crawled : 15:00) - globenewswire.com
BGXX | $0.2004 -5.61% -5.94% 500K
|
|
| O: -0.14%
H: 158.62%
C: 45.93%
drug million expansion
Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
Published: 2024-03-01 (Crawled : 15:00) - biospace.com/
MNKKQ | $0.02
|
Manufacturing
| Email alert
Add to watchlist
MNK | $0.3402 -0.06% 540K
|
n/a
| Email alert
Add to watchlist
MNKPF | $17.25
|
n/a
| Email alert
Add to watchlist
MNKTQ | $0.12 -66.67% 39K
|
Manufacturing
| Email alert
Add to watchlist
acthar fda drug approval gel application
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
Published: 2024-02-15 (Crawled : 15:00) - biospace.com/
LTRN | News | $5.7 6.74% 6.32% 260K
|
Health Technology
|
| O: -0.25%
H: 3.17%
C: -0.74%
pharma drug unique tumor program
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Published: 2024-02-14 (Crawled : 15:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.23%
H: 0.44%
C: 0.14%
drug review food tumors treatment application advanced
BMS, J&J and Merck CEOs Push Back in Senate Hearing on High Drug Prices
Published: 2024-02-09 (Crawled : 15:00) - biospace.com/
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
drug back merck
J&J Lawsuit Asserts Employer Liability for High Drug Costs
Published: 2024-02-08 (Crawled : 15:00) - biospace.com/
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
drug
Revolutionizing Therapeutics: The Next Generation Sequencing Boom in Global Drug R&D | BCC Research
Published: 2024-02-06 (Crawled : 15:00) - prnewswire.com
TMO | News | $548.38 0.66% 0.29% 1.5M
|
Health Technology
|
| O: 0.16%
H: 1.45%
C: 1.41%
BIO | $280.13 0.14% 0.0% 180K
|
Health Technology
|
| O: 0.34%
H: 1.85%
C: 1.63%
A | $133.91 0.89% 0.0% 850K
|
Health Technology
|
| O: -0.13%
H: 2.6%
C: 2.42%
drug research global
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Published: 2024-02-05 (Crawled : 15:00) - biospace.com/
AIMD | $1.02 -0.97% -0.98% 12K
|
Manufacturing
|
| O: 11.65%
H: 0.0%
C: -6.09%
covid-19 fda drug resolve trial response
Senator Sanders Warns J&J, Merck CEOs Could Be Subpoenaed on Drug Pricing
Published: 2024-01-19 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: -0.83%
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: 0.67%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.23%
H: 0.0%
C: 0.0%
drug merck
Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug
Published: 2024-01-17 (Crawled : 15:00) - biospace.com/
EVGN | $0.7 -13.64% 63K
|
Health Technology
|
| O: -4.74%
H: 1.34%
C: -4.91%
drug trial
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
EWTX | $15.05 -1.18% -1.2% 380K
|
Manufacturing
|
| O: 3.35%
H: 7.88%
C: -6.03%
fda rare drug disease program
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
LTRN | News | $5.7 6.74% 6.32% 260K
|
Health Technology
|
| O: 2.81%
H: 0.0%
C: -1.74%
lp-284 fda pharma drug candidate designation lymphomas grants
Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen
Published: 2023-10-27 (Crawled : 15:00) - globenewswire.com
PMD | $2.57 5.54% 2.1K
|
Health Services
|
| O: 2.12%
H: 2.07%
C: 1.66%
drug
World Precision Instruments Expands EVOM™ Auto with Both 24 and 96 Multiwell Plate Capability, Combining Transepithelial Electrical Resistance (TEER) Measurements with a High Throughput Format for Drug Discovery
Published: 2023-10-23 (Crawled : 15:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
drug world
Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company’s Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence
Published: 2023-10-19 (Crawled : 15:00) - adialpharma.com
ADIL | News | $1.895 -1.81% -1.85% 2.5M
|
Health Technology
|
| O: 0.18%
H: 11.51%
C: 1.44%
ad04 alcohol drug patent diagnostic genetic treat pharmaceuticals
New Investigational Drug Offers Relief for Treatment-Resistant Epilepsy Patients
Published: 2023-10-09 (Crawled : 15:00) - prnewswire.com
XENE | $40.0 0.3% 0.3% 390K
|
Health Technology
|
| O: -0.62%
H: 1.44%
C: 0.28%
drug
Global Sustained Release Excipients Markets, 2017-2022, 2022-2027F, 2032F: Escalating Demand for Advanced Drug Formulations, Fueled by Higher Prevalence of Chronic and Acute Diseases
Published: 2023-09-29 (Crawled : 15:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: -1.26%
AZNCF | News | $136.2 -4.19% 1.7K
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: -1.46%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: 1.18%
H: 0.06%
C: -1.62%
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.52%
H: 0.37%
C: -0.77%
AZN | News | $70.12 2.29% 2.24% 4.8M
|
Health Technology
|
| O: 2.02%
H: 0.0%
C: -1.54%
drug global
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
Published: 2023-09-28 (Crawled : 15:00) - biospace.com/
EDSA | $4.46 0.22% 0.22% 810
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -9.07%
drug candidate biotech results phase 2
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.